Charles River Labs (CRL) Guides FY13 EPS Below Views
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $229.16 +0.41%
EPS Growth %: -12.2%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
DBVT, FNGR, SFNC, More
EPS Growth %: -12.2%
Financial Fact:
Interest expense: -7.08M
Today's EPS Names:
DBVT, FNGR, SFNC, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) provided guidance for 2013 and reaffirmed guidance for 2012.
James C. Foster, Chairman, President and Chief Executive Officer, said, “The actions we have taken in the last three years to enhance our in vivo biology portfolio, improve our operating efficiency, and forge stronger relationships with our clients have positioned us exceptionally well to be the partner of choice for early-stage drug discovery and development products and services. We believe these are the reasons that we were awarded two large, strategic partnerships in the last year, and that we will prevail in the majority of the ongoing discussions concerning additional opportunities. These partnerships, combined with market share gains we have made in our mid-tier biopharmaceutical and academic client bases, are the foundation of improved performance in 2013 and beyond.”
“As a result, we are confident that sales growth will accelerate in 2013, to a range of 3% to 5% on a constant currency basis, and that non-GAAP earnings per share will increase at a slightly higher rate, to a range of $2.80 to $2.90.”
2013 Guidance
Sales and earnings per share guidance for 2013 excludes the impact of acquisitions until the transaction has been completed. The Company continues to expect that the acquisition of Vital River will be completed in the first quarter of 2013.
*** The Street sees FY13 sales of $1.18 billion and EPS of $3.02.
James C. Foster, Chairman, President and Chief Executive Officer, said, “The actions we have taken in the last three years to enhance our in vivo biology portfolio, improve our operating efficiency, and forge stronger relationships with our clients have positioned us exceptionally well to be the partner of choice for early-stage drug discovery and development products and services. We believe these are the reasons that we were awarded two large, strategic partnerships in the last year, and that we will prevail in the majority of the ongoing discussions concerning additional opportunities. These partnerships, combined with market share gains we have made in our mid-tier biopharmaceutical and academic client bases, are the foundation of improved performance in 2013 and beyond.”
“As a result, we are confident that sales growth will accelerate in 2013, to a range of 3% to 5% on a constant currency basis, and that non-GAAP earnings per share will increase at a slightly higher rate, to a range of $2.80 to $2.90.”
2013 Guidance
Sales and earnings per share guidance for 2013 excludes the impact of acquisitions until the transaction has been completed. The Company continues to expect that the acquisition of Vital River will be completed in the first quarter of 2013.
*** The Street sees FY13 sales of $1.18 billion and EPS of $3.02.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Verizon to cut 3,000 jobs as it shifts stores to franchises
- Simmons First National Corp (SFNC) Misses Q2 EPS by 2c
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Create E-mail Alert Related Categories
Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
